The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity

Bone Marrow Transplantation

Volumn 25, Issue 9, 2000, Pages 915-924

  Hassan, M ^a,b,c,d   Ljungman, P ^a   Ringden O ^d   Hassan, Z ^c   Oberg G ^e   Nilsson, C ^a,c   Bekassy A ^e   Bielenstein, M ^f   Abdel Rehim, M ^g   Georen S ^c   Astner, L ^f  

^a KFC Novum   (Sweden)

^b Division of Pharmacology   (Sweden)

^c KFC Novum   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f Apoteks Central Laboratory ACL   (Sweden)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bone marrow transplantation; Busulphan; Cyclophosphamide; Drug interaction; Pharmacokinetics

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SCHOOL CHILD; VEIN OCCLUSION; WHOLE BODY RADIATION;

EID: 0034021677     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702377     Document Type: Article

References (56)

1. Lucarelli G, Galimberti M, Giardini C et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270-275.
2. Santos GW, Saral R, Burns WH et al. Allogeneic, syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas - Baltimore experiences. Acta Haematol 1987; 78 (Suppl. 1): 175-180.
3. Santos GW. Busulfan and cyclophosphamide versus cyclophosphamide and total body irradiation for marrow transplantation in chronic myelogenous leukemia - a review. Leuk Lymphoma 1993; 11 (Suppl. 1): 201-204.
4. Ringden O, Ruutu T, Remberger M et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
5. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
6. Ringden O, Labopin M, Tura S et al. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 93: 637-645.
7. Blaise D, Maraninchi D, Archimbaud E et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578-2582.
8. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
9. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
10. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991; 20: 194-208.
11. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
12. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
13. Angelucci E, Mariotti E, Lucarelli G et al. Sudden cardiac tamponade after chemotherapy for marrow transplantation in thalassaemia. Lancet 1992; 339: 287-289.
14. Brugieres L, Hartmann O, Travagli JP et al. Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome. J Clin Oncol 1989; 7: 194-199.
15. Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984; 68: 1247-1254.
16. Slattery JT, Kalhorn TF, McDonald GB et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996; 14: 1484-1494.
17. Sandstrom M, Freijs A, Larsson R et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996; 14: 1581-1588.
18. Struck RF, Alberts DS, Horne K et al. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, cross-over trial. Cancer Res 1987; 47: 2723-2726.
19. Moore MJ, Hardy RW, Thiessen JJ et al. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 1988; 44: 622-628.
20. Schuler U, Ehninger G, Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother Pharmacol 1987; 20: 248-252.
21. Ren S, Kalhorn TF, McDonald GB et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 1998; 64: 289-301.
22. Moore MJ, Erlichman C, Thiessen JJ et al. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 1994; 33: 472-476.
23. Walker D, Flinois JP, Monkman SC et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47: 1157-1163.
24. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57: 4229-4235.
25. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17: 146S-154S.
26. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994; 54: 6215-6220.
27. Crook TR, Souhami RL, Whyman GD, McLean AE. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res 1986; 46: 5035-5038.
28. Hassan M, Ehrsson H. Metabolism of 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 1987; 12: 71-76.
29. Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat. Drug Metab Dispos 1987; 15: 399-402.
30. Hassan M, Ehrsson H, Wallin I, Eksborg S. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. Eur J Drug Metab Pharmacokinet 1988; 13: 301-305.
31. Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 1998; 26: 52-55.
32. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56: 3678-3681.
33. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24: 1015-1019.
34. Hardy RW, Erlichman C, Soldin SJ. High-performance liquid chromatographic measurement of cyclophosphamide in serum. Ther Drug Monit 1984; 6: 313-318.
35. Johansson M, Bielenstein M. Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography. J Chromatogr B Biomed Appl 1994; 660: 111-120.
36. Hassan M, Ehrsson H. Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 1983; 277: 374-380.
37. Jones RJ, Lee KS, Beschorner WE et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
38. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
39. Chen TL, Kennedy MJ, Anderson LW et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997; 25: 544-551.
40. Sladek NE, Powers JF, Grage GM. Half-life of oxazaphosphorines in biological fluids. Drug Metab Dispos 1984; 12: 553-559.
41. Ducharme MP, Bernstein ML, Granvil CP et al. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers. Cancer Chemother Pharmacol 1997; 40: 531-533.
42. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
43. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57: 1946-1954.
44. Marchand DH, Remmel RP, Abdel-Monem MM. Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab Dispos 1988; 16: 85-92.
45. Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509-5516.
46. Hassan M, Oberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
47. Damani LA, Houdi AA. Cytochrome P-450 and FAD-monooxygenase mediated S-and N-oxygenations. Drug Metab Drug Interact 1988; 6: 235-244.
48. Sherratt AJ, Damani LA. Activities of cytosolic and microsomal drug oxidases of rat hepatocytes in primary culture. Drug Metab Dispos 1989; 17: 20-25.
49. Lee KE, Mayer RD, Cockett AT. Effect of systemic glutathione depletion by buthionine sulfoximine on sensitivity of murine bladder cancer to cytotoxic agents. Urology 1989; 34: 376-380.
50. Lee FY. Glutathione diminishes the anti-tumour activity of 4-hydroperoxycyclophosphamide by stabilising its spontaneous breakdown to alkylating metabolites. Br J Cancer 1991; 63: 45-50.
51. Levine ES, Friedman HS, Griffith OW et al. Cardiac cell toxicity induced by 4-hydroperoxycyclophosphamide is modulated by glutathione. Cardiovasc Res 1993; 27: 1248-1253.
52. Gurtoo HL, Hipkens JH, Sharma SD. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res 1981; 41: 3584-3591.
53. Peters RH, Jollow DJ, Stuart RK. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res 1991; 51: 2536-2541.
54. Yuan ZM, Smith PB, Brundrett RB et al. Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metab Dispos 1991; 19: 625-629.
55. Friedman HS, Colvin OM, Aisaka K et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res 1990; 50: 2455-2462.
56. Shulman HM, Luk K, Deeg HJ et al. Induction of hepatic veno-occlusive disease in dogs (published erratum appears in Am J Pathol 1987; 127: 198). Am J Pathol 1987; 126: 114-125.